Altimmune shareholders approved increase in authorized common shares to 400 million

• Altimmune held its annual shareholder meeting on April 16, 2026.
• Shareholders backed an amendment to increase authorized common shares to 400,000,000 from 200,000,000.
• Investors ratified Ernst & Young as independent registered public accounting firm for year ending December 31, 2026.
• Holders endorsed an amendment to 2019 employee stock purchase plan, lifting shares reserved to 1,108,827 from 403,500.
• Shareholders authorized adjournment of meeting to allow additional proxy solicitation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Altimmune Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001326190-26-000027), on April 16, 2026, and is solely responsible for the information contained therein.